Alembic Pharma gets USFDA EIR for Panelav facility
New Delhi: Alembic Pharmaceuticals on Friday said it has received establishment inspection report (EIR) from the US health regulator for its Panelav facility in Gujarat.
The company has received EIR from the US Food and Drug Administration (USFDA) for the inspection carried out by them on its general oral solid formulation facility at Panelav, from March 9 to March 13, Alembic Pharmaceuticals said in a filing to the BSE.
"With this, EIR is in place for all our manufacturing facilities for international markets," it added.
Shares of Alembic Pharmaceuticals were trading at Rs 940.05 per scrip on the BSE, up 3.50 per cent from its previous close.
Read also: Alembic Pharma iron tablet Deferasirox gets USFDA nod
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.
Read also: Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for Adapalene Gel
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.